AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01149564
Drug: iv ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01149564
Drug: oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01598064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 pack tid po
Trial: NCT02271646
Drug: 0.5% marcaine 20ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
Trial: NCT03633123
Drug: D_PLEX
RxNorm normalized name: Kleer Plex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
Trial: NCT02838797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral acetate buffer
Trial: NCT01534442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03532802
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week
Trial: NCT01876290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01876316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 400mg of placebo
Trial: NCT03527771
Drug: telephone-assisted CPR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency call with telephone assistance in CPR
Trial: NCT00126256
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01542489
Drug: human soluble insulin
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Trial: NCT01450306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
Trial: NCT02829320
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
Trial: NCT00740363
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active sitagliptin treatment for 4 weeks
Trial: NCT04439474
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, patients receive their usual medications and treatments
Trial: NCT01020630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
Trial: NCT00320710
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg IV
Trial: NCT00320710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to zoledronic acid
Trial: NCT02801617
Drug: PRO-067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
Trial: NCT02801617
Drug: GAAP Ofteno®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop QD during 30 days Active comparator, reference medication.
Trial: NCT02348918
Drug: Luminate 1.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02348918
Drug: Luminate 2.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02348918
Drug: Luminate 3.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02348918
Drug: Luminate 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00680095
Drug: AN2690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 Solution, 2.5%, Daily for up to 21 days
Trial: NCT00680095
Drug: AN2690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 Solution, 7.5%, Daily for up to 21 days
Trial: NCT00680095
Drug: AN2690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 Solution, 5.0%, Daily for up to 21 days
Trial: NCT01411150
Drug: Creatine Monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 30 grams daily creatine monohydrate
Trial: NCT01164579
Drug: Tasocitinib plus Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
Trial: NCT01164579
Drug: Tofacitinib plus placebo methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
Trial: NCT06110494
Drug: Iron oxide nanoparticles treatment Ferumoxytol/H2O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
Trial: NCT06110494
Drug: supplementary irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Trial: NCT04445038
Drug: 610
RxNorm normalized name: AY-6108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant anti-IL-5 Humanized Monoclonal Antibody
Trial: NCT04445038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00584493
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206.
Trial: NCT02431286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
Trial: NCT05486195
Drug: SDI-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDI-118 Powder in Capsule
Trial: NCT05486195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT02079350
Drug: %6 HES and %4 Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01961739
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application, twice per day for 15 consecutive days
Trial: NCT01541332
Drug: Pegylated Liposomal Doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle.
Trial: NCT01245959
Drug: Docetaxel, cisplatin and fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Trial: NCT01511978
Drug: Continuous 3,4-DAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
Trial: NCT01511978
Drug: Taper 3,4-DAP to Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
Trial: NCT00771342
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
Trial: NCT04424420
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen oral tablet
Trial: NCT04424420
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
Trial: NCT04615013
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Not applicable to this study
Trial: NCT04615013
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Not applicable to this study
Trial: NCT04615013
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Not applicable to this study
Trial: NCT01866111
Drug: YKP3089
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01866111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02486601
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
Trial: NCT01004497
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
Trial: NCT00504712
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustanon- 200mg- Intramuscular testosterone every 2 weeks
Trial: NCT00086138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo designed to mimic sertraline taken daily for 24 weeks
Trial: NCT01146548
Drug: FLUOXETINE
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
Trial: NCT01359852
Drug: [11C] JNJ-42491293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
Trial: NCT03143725
Drug: GLPG1972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
Trial: NCT00460811
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily
Trial: NCT02097745
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a 10-25 mg stable dose given orally or parenterally throughout study
Trial: NCT01071564
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01359852
Drug: [11C] JNJ-42491293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
Trial: NCT03418688
Drug: COR388
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COR388 administered for 10 or 28 days.
Trial: NCT03418688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 10 or 28 days.
Trial: NCT04601077
Drug: Nitric Oxide lozenges, 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric Oxide lozenge, 30 mg twice a day for 30 days
Trial: NCT04601077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
Trial: NCT02589639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02589639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For blinding purposes
Trial: NCT01877642
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler
Trial: NCT01877642
Drug: Placebo IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular placebo to mimic lorazepam 1 mg IM
Trial: NCT01082705
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
Trial: NCT00552396
Drug: Anti-KIR (1-7F9)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human monoclonal antibody
Trial: NCT00961350
Drug: PA32540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
Trial: NCT00961350
Drug: EC Aspirin 325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
Trial: NCT01812954
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01316939
Drug: GSK1605786A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1605786A 500 milligrams once daily
Trial: NCT01316939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01316939
Drug: GSK1605786A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1605786A 500 milligrams twice daily
Trial: NCT03894189
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
Trial: NCT00604591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg by mouth three times a day
Trial: NCT02318446
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
Trial: NCT00713947
Drug: during one week for the active treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: during one week for the active treatments placebo during 25 weeks
Trial: NCT00713947
Drug: Placebo Formula 515
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 weeks, one tablet per day
Trial: NCT05288660
Drug: ALXN1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.
Trial: NCT05288660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
Trial: NCT02073929
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c. daily for 26 weeks
Trial: NCT00433589
Drug: anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00433589
Drug: docetaxel and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04423744
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT04423744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo as film-coated tablet
Trial: NCT00263705
Drug: Adjuvant capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2000 mg/m² daily six cycles
Trial: NCT00263705
Drug: capecitabine in aduvant setting
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine in aduvant setting in ederly with breast cancer
Trial: NCT01124760
Drug: AZD9742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
Trial: NCT00072280
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
Trial: NCT01743560
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Trial: NCT00481351
Drug: Simvastatin 20mg plus ezetimibe 10mg
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
Trial: NCT00481351
Drug: simvastatin 20mg
RxNorm normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20mg once a day
Trial: NCT00481351
Drug: Simvastatin 80mg
RxNorm normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
Trial: NCT04080388
Drug: Anti-congestive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation of in-hospital anti-congestive treatment
Trial: NCT04173780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop per day in both eyes for 1 year
Trial: NCT00975611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets BID, for 4 weeks
Trial: NCT02056015
Drug: [68Ga]MLN6907
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Administration of \[68Ga\]MLN6907 on Day 1
Trial: NCT00612274
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
Trial: NCT00813150
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
Trial: NCT02772211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day
Trial: NCT00454688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
Trial: NCT03368092
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.